Search Results - Retina Today

Sort By:

Relevance Date

Relevance

Date

March 2024 Insert

Leveraging Siglec Receptors to Repolarize Macrophages for the Treatment of Geographic Atrophy

How moving beyond complement targets may lead to true maintenance of vision and greater reduction in GA lesion growth rates.

David Callanan, MD; Tarek S. Hassan, MD; and Derek Kunimoto, MD, JD

January/February 2024 | Features

Surgical Drug Delivery Roundup

These novel innovations have helped clinicians improve therapeutic access to the posterior pole.

Nikhil Bommakanti, MD; Michael A. Klufas, MD; and David Xu, MD

September 2015 | Special Focus: Drug Delivery

Drug Delivery to the Posterior Segment

A review of methods and technologies available and those on the horizon.

Daniel D. Esmaili, MD, and David S. Boyer, MD

July/August 2013

Drug Delivery to the Posterior Segment: An Update

Many routes for sustained drug delivery to the retina are in use or being explored.

David S. Boyer, MD

July/August 2012 | New: The Hot Button

The Impact of Recent Regulatory Decisions Regarding the Iluvien Intravitreal Implant

Robert L. Avery, MD; David M. Brown, MD; and Baruch D. Kuppermann, MD, PhD

July/August 2011 Insert

Injection Techniques for the Dexamethasone Intravitreal Implant

This insert to Retina Today is sponsored by Allergan, Inc.

July/August 2011 Insert

Injection Techniques for the Dexamethasone Intravitreal Implant

This insert to Retina Today is sponsored by Allergan, Inc.

July 2008

Visualization in Vitrectomy Procedures

FDA-approved injectable triamcinolone acetonide is formulated for intraocular use.

Seenu M. Hariprasad, MD, and David S. Dyer, MD

September 2006

Clinical Trial Update: AMD

Trial: A Phase 4, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Pegaptanib Sodium (Macugen) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement